Axovant spinoff Arvelle Therapeutics received $180m in the LSP-led series A round, and will focus on the development of a recently licensed epilepsy drug.

Sachin Bansal, co-founder of e-commerce company Flipkart, has contributed $92m to corporate-backed Ola’s $1bn series J round, following reports last month that suggested he had committed $21m.

Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.

Opendoor, whose shareholders include GV and SoftBank Vision Fund, is reportedly seeking $200m at a $3.7bn valuation, which would take its total funding to $1.25bn.

Passage Bio has launched to develop treatments for diseases affecting the central nervous system, after raising almost $116m in a series A round backed by Lilly Asia Ventures.

Tencent made a significant cash commitment by leading a round raised by online social forum Reddit at $3bn post-money valuation

Axovant Sciences has spun out its small molecule team into a startup called Arvelle, which will develop an anti-epileptic drug after raising more than $100m in external funding.

Didi Chuxing has invested $100m in the hotel platform, allowing Oyo to close a $1bn round led by SoftBank Vision Fund and backed by Grab.

Lilly Asia Ventures had contributed to cancer diagnostics technology provider Burning Rock's series C round, which was led by GIC.

The conglomerate has paid approximately $256m for a 20% stake in smart energy distributor and technology provider Ovo Energy.